Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients
Open Access
- 9 February 2022
- Vol. 12 (2), e054669
- https://doi.org/10.1136/bmjopen-2021-054669
Abstract
Objective To estimate the US incidence of thrombotic events and related rare diagnoses. Design Claims-based retrospective cohort study of incidence. Setting US commercial health insurance administrative claims database. Participants Adults 25–64 years of age between 2015 and 2019 with a minimum of 12 consecutive thrombosis-free months of continuous enrolment beginning 2014 were selected. Main outcomes Age (10-year intervals) and sex stratum-specific incidence rates per 100 000 person-years were determined for venous thromboembolism (VTE), cerebral venous thrombosis (CVT) and other major venous thrombotic events, and events of special interest, including immune thrombocytopenic purpura (ITP), haemolytic-uremic syndrome (HUS) and heparin-induced thrombocytopenia (HIT). Results Of 13 249 229 enrollees (half female/male), incidence of venous thromboembolic events (deep vein thrombosis (DVT), pulmonary embolism (PE), CVT or other major venous thrombotic conditions) was 247.89 per 100 000 person-years (95% CI: 245.96 to 249.84). Incidence of VTE was 213.79 with ICD codes alone (95% CI: 211.99 to 215.59) and 129.34 (95% CI: 127.95 to 130.75) when also requiring a filled anticoagulation prescription or an inferior vena cava (IVC) filter. Incidence was 6.37 for CVT (95% CI: 6.07 to 6.69), 26.06 for ITP (95% CI: 25.44 to 26.78), 0.94 for HUS (95% CI: 0.82 to 1.06) and 4.82 for HIT (95% CI: 4.56 to 5.10). The co-occurrence of CVT with either ITP or HIT (diagnoses within 14 days of one another) was 0.090 (95% CI: 0.06 to 0.13). Incidence tended to increase with age and was higher for women under 55. Incidence for CVT, HUS and CVT with ITP or HIT was higher for women in all age groups. Incidence of PE and CVT increased significantly over the 5-year period, while DVT rates decreased. Conclusions These results are the first US estimates for the incidence of thrombotic and rare events of interest in a large, commercially insured US population. Findings provide a critically important reference for determining excess morbidity associated with COVID-19 and more generally for vaccine pharmacovigilance.Keywords
Funding Information
- Sealy Center For Vaccine Sciences (N/A)
- Texas Academy of Family Physicians (N/A)
This publication has 22 references indexed in Scilit:
- Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously ThoughtStroke, 2016
- Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US femalesVaccine, 2015
- Secular Trends in Occurrence of Acute Venous Thromboembolism: The Worcester VTE Study (1985-2009)American Journal Of Medicine, 2014
- The Incidence of Cerebral Venous ThrombosisStroke, 2012
- Incidence and mortality of venous thrombosis: a population‐based studyJournal of Thrombosis and Haemostasis, 2007
- Venous thromboembolism: disease burden, outcomes and risk factorsJournal of Thrombosis and Haemostasis, 2005
- Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996Thrombosis and Haemostasis, 2005
- Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiologyAmerican Journal Of Medicine, 2004
- Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.2000
- Trends in the Incidence of Deep Vein Thrombosis and Pulmonary EmbolismArchives of Internal Medicine, 1998